Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Endocrine System

Endocrine System

Recruiting

Investigating islet cell infusion in people with type 1 diabetes and kidney transplant

The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for patients with type 1 diabetes who have a kidney transplant.

Status
Recruiting
Principal Investigator
Breay Paty
Body Locations and Systems
Endocrine System
Age
18-65

Investigating a treatment for moderate-to-severe active thyroid eye disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of subcutaneous teprotumumab in participants with moderate-to-severe active thyroid eye disease (TED). TED is an autoimmune disease in which the eye muscles and fatty tissue behind the eye become inflamed. This can push the eyes forward (bulging) or cause redness and swelling. Symptoms can range from mild to sight-threatening. Current treatment options for moderate/severe TED are not optimal (lots of side effects), but teprotumumab holds promise and is being tested for treatment of TED in this trial.

Status
Recruiting
Principal Investigator
Vivian Yin
Body Locations and Systems
Thyroid
Eyes and Vision

Investigating endometriosis and brown adipose tissue activity

The purpose of this study is to compare brown adipose tissue (BAT) activity in women/people diagnosed with endometriosis to similar healthy controls. BAT activity is measured twice in a random order during the early part of the menstrual cycle (follicular phase) and following egg release/ovulation (luteal phase). The study team will investigate whether BAT activity in women with endometriosis differs from healthy control women who are of similar age and body mass index.

Status
Recruiting
Principal Investigator
Jerilynn C. Prior
Body Locations and Systems
Endocrine System
Endometriosis
Sexual Health
Age
19-35

Evaluating the efficacy of islet cell therapy for type 1 diabetes

The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for type 1 diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar. 

Status
Recruiting
Principal Investigator
Breay Paty
Body Locations and Systems
Endocrine System
Age
18-65

Evaluating a virtual program for peer-led mental health support

The purpose of this study is to evaluate a peer-led mental health support program, REACHOUT, for rural and remote communities in British Columbia. REACHOUT is a mobile app that provides free peer-led mental health support to adults with type 1 diabetes (T1D). The REACHOUT intervention spans over six months and empowers adults with T1D to join as either a peer supporter, who will be trained to provide social and emotional assistance, or as a participant, who will receive invaluable support from empathetic peer supporters.

Status
Recruiting
Principal Investigator
Tricia Tang
Body Locations and Systems
Endocrine System
Age
19 and above

Developing a strategy to prevent hepatitis C virus reinfection

The purpose of this study is to measure patterns of hepatitis C virus (HCV) reinfection after achieving an undetectable viral load at end of treatment on direct-acting aniviral therapy; to determine the threshold of risk reduction practices that protects against HCV reinfection after achieving an undetectable viral load; and to evaluate the potential impact of successful HCV treatment in terms of health care costs and resource utilization.

Status
Recruiting
Body Locations and Systems
Endocrine System
Kidneys and Urinary System
Age
19 and above

Cyclic P4/Spironolactone in PCOS

The purpose of the study is to learn about the impacts of Cyclic Progesterone and Spironolactone on the menstrual cycles, luteinizing hormone and testosterone levels, and quality of life experiences of women living with polycystic ovary syndrome (PCOS).

Recruitment Poster

Status
Recruiting
Principal Investigator
Jerilynn C. Prior
Body Locations and Systems
Endocrine System
Skin, Hair and Nails
Age
19-35

Glucose Variability in Subclinical Hypertrophy

Evaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption. In this study investigators propose to enroll at least 20 people who participated in phase 1 and who were determined to have subclinical lipohypertrophy to examine the correlation between glycemic control and amount of insulin injected in subclinical hypertrophic areas using capillary blood glucose and continuous glucose monitoring.

Status
Recruiting
Principal Investigator
Graydon Meneilly
Body Locations and Systems
Diabetes - Type 1
Diabetes - Type 2
Area
Vancouver
Age
19 and above

From Clinic to Community Study (C2C)

This study is a 12-month study. There are two different groups in the study. Both groups will enter the study after the graduation from 8-hour diabetes education course taught at VGH, St. Paul's, or Richmond Hospital. The first group will receive on-going support from their peers who have diabetes and are trained specifically to help other patients with diabetes. The second group will receive the usual care.

Status
Recruiting
Principal Investigator
Tricia Tang
Body Locations and Systems
Diabetes - Type 2
Area
Vancouver
Age
21 and above

Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease (CRISEPTED)

Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface, ocular movement restriction and double vision, and optic nerve compression and loss of vision.

First line medical therapy is oral or intravenous corticosteroids (CS), which several studies have shown results in reduction of soft tissue congestion, but some studies suggesting that ocular restriction or visual loss may still occur in spite of CS therapy.

Status
Recruiting
Principal Investigator
Peter Dolman
Body Locations and Systems
Eye Disorders
Thyroid
Area
Vancouver
Age
35 and above

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)

In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections. Even with insulin injections, blood glucose (sugar) control is imperfect and leads to many health complications and a shortened life span. This is a pilot clinical trial to test the safety of a drug, ustekinumab, in 20 adult subjects with recent-onset T1D.

Status
Recruiting
Principal Investigator
Thomas Elliott
Body Locations and Systems
Diabetes - Type 1
Area
Vancouver
Age
18-35

Closed for Recruitment

Bexagliflozin Efficacy and Safety Trial (BEST)

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.

The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.

Status
Closed for Recruitment
Principal Investigator
G.B. John Mancini
Body Locations and Systems
Diabetes - Type 2
Area
Vancouver
Age
40 and above

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

Status
Closed for Recruitment
Principal Investigator
Nadia Zalunardo
Body Locations and Systems
Diabetic Kidney Problems
Diabetes - Type 2
Area
Vancouver
Age
30 and above

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

Status
Closed for Recruitment
Principal Investigator
Graham Wong
Body Locations and Systems
Diabetes - Type 2
Coronary Artery Disease
Area
Vancouver
Age
40 and above

Effects of Sedentary Behaviour on Metabolic Parameters

The rates of sedentary activity are increasing. Studies have shown that time spent on doing sedentary activities is an independent risk factor for cardiovascular disease. Prior studies have shown that interrupting inactivity improved the body's handling of blood glucose and gene expression. The investigators plan to explore this further by examining the effects of interrupting 4 hours of inactivity with 2 minutes of moderate intensity exercise every 20 minutes on the following metabolic parameters: blood pressure, cortisol, C-Reactive Protein, glucose and insulin levels.

Status
Closed for Recruitment
Principal Investigator
Kenneth Madden
Body Locations and Systems
Diabetes - Type 2
Area
Vancouver
Age
65 and above
Subscribe to Endocrine System

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy